Literature DB >> 33809587

Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study.

Emanuele Rinninella1, Antonia Strippoli2, Marco Cintoni3, Pauline Raoul4, Raffaella Vivolo2, Mariantonietta Di Salvatore2, Enza Genco5, Riccardo Manfredi5, Emilio Bria2,4, Giampaolo Tortora2,4, Antonio Gasbarrini4,6, Carmelo Pozzo2, Maria Cristina Mele4,7.   

Abstract

BACKGROUND: The impact of the new chemotherapy, fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) on body composition in gastric cancer (GC) patients remains unknown. We assessed body composition changes of GC patients receiving the FLOT regimen and their impact on treatment outcomes.
METHODS: Preoperative pre- and post-FLOT computed tomography (CT) scans of advanced GC patients were studied. Lumbar skeletal muscle index (SMI) and adipose indices were calculated before and after FLOT.
RESULTS: A total of 26 patients were identified between April 2019 and January 2020. Nineteen patients were sarcopenic at diagnosis. The mean BMI decreased (from 24.4 ± 3.7 to 22.6 ± 3.1; p < 0.0001) as well as the SMI (from 48.74 ± 9.76 to 46.52 ± 9.98; p = 0.009) and visceral adipose index (VAI) (from 49.04 ± 31.06 to 41.99 ± 23.91; p = 0.004) during preoperative FLOT therapy. BMI, SMI, and VAI variations were not associated with toxicity, Response Evaluation Criteria in Solid Tumors (RECIST), response, delay and completion of perioperative FLOT chemotherapy, and the execution of gastrectomy; a decrease of SMI ≥ 5% was associated with a higher Mandard tumor regression grade (p = 0.01).
CONCLUSIONS: Almost three-quarters (73.1%) of GC patients were sarcopenic at diagnosis. Preoperative FLOT was associated with a further reduction in SMI, BMI, and VAI. These changes were not associated with short-term outcomes.

Entities:  

Keywords:  FLOT; SMI; adipose tissue; body composition; gastric cancer; muscle mass; neoadjuvant chemotherapy; personalized medicine; sarcopenia; toxicity

Mesh:

Substances:

Year:  2021        PMID: 33809587      PMCID: PMC7999770          DOI: 10.3390/nu13030960

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  39 in total

1.  Postoperative complications in gastrointestinal cancer patients: the joint role of the nutritional status and the nutritional support.

Authors:  Federico Bozzetti; Luca Gianotti; Mario Braga; Valerio Di Carlo; Luigi Mariani
Journal:  Clin Nutr       Date:  2007-08-01       Impact factor: 7.324

2.  GLIM Criteria for the Diagnosis of Malnutrition: A Consensus Report From the Global Clinical Nutrition Community.

Authors:  Gordon L Jensen; Tommy Cederholm; M Isabel T D Correia; M Christina Gonzalez; Ryoji Fukushima; Takashi Higashiguchi; Gertrudis Adrianza de Baptista; Rocco Barazzoni; Renée Blaauw; Andrew J S Coats; Adriana Crivelli; David C Evans; Leah Gramlich; Vanessa Fuchs-Tarlovsky; Heather Keller; Luisito Llido; Ainsley Malone; Kris M Mogensen; John E Morley; Maurizio Muscaritoli; Ibolya Nyulasi; Matthias Pirlich; Veeradej Pisprasert; Marian de van der Schueren; Soranit Siltharm; Pierre Singer; Kelly A Tappenden; Nicolas Velasco; Dan L Waitzberg; Preyanuj Yamwong; Jianchun Yu; Charlene Compher; Andre Van Gossum
Journal:  JPEN J Parenter Enteral Nutr       Date:  2018-09-02       Impact factor: 4.016

3.  Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Ralf D Hofheinz; Claudia Pauligk; Hans-Georg Kopp; Georg Martin Haag; Kim Barbara Luley; Johannes Meiler; Nils Homann; Sylvie Lorenzen; Harald Schmalenberg; Stephan Probst; Michael Koenigsmann; Matthias Egger; Nicole Prasnikar; Karel Caca; Jörg Trojan; Uwe M Martens; Andreas Block; Wolfgang Fischbach; Rolf Mahlberg; Michael Clemens; Gerald Illerhaus; Katja Zirlik; Dirk M Behringer; Wolff Schmiegel; Michael Pohl; Michael Heike; Ulrich Ronellenfitsch; Martin Schuler; Wolf O Bechstein; Alfred Königsrainer; Timo Gaiser; Peter Schirmacher; Wael Hozaeel; Alexander Reichart; Thorsten O Goetze; Mark Sievert; Elke Jäger; Stefan Mönig; Andrea Tannapfel
Journal:  Lancet Oncol       Date:  2016-10-22       Impact factor: 41.316

4.  Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.

Authors:  Keiji Sugiyama; Yukiya Narita; Seiichiro Mitani; Kazunori Honda; Toshiki Masuishi; Hiroya Taniguchi; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Masahiro Tajika; Kei Muro
Journal:  Anticancer Res       Date:  2018-10       Impact factor: 2.480

5.  NutriCatt protocol in the Enhanced Recovery After Surgery (ERAS) program for colorectal surgery: The nutritional support improves clinical and cost-effectiveness outcomes.

Authors:  Emanuele Rinninella; Roberto Persiani; Domenico D'Ugo; Francesco Pennestrì; Americo Cicchetti; Eugenio Di Brino; Marco Cintoni; Giacinto Abele Donato Miggiano; Antonio Gasbarrini; Maria Cristina Mele
Journal:  Nutrition       Date:  2018-02-05       Impact factor: 4.008

6.  Sarcopenia is highly prevalent in patients undergoing surgery for gastric cancer but not associated with worse outcomes.

Authors:  Juul J W Tegels; Jeroen L A van Vugt; Kostan W Reisinger; Karel W E Hulsewé; Anton G M Hoofwijk; Joep P M Derikx; Jan H M B Stoot
Journal:  J Surg Oncol       Date:  2015-08-31       Impact factor: 3.454

7.  Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer.

Authors:  Norihiro Matsuura; Masaaki Motoori; Kazumasa Fujitani; Yujiro Nishizawa; Hisateru Komatsu; Yasuhiro Miyazaki; Susumu Miyazaki; Akira Tomokuni; Takamichi Komori; Kazuhiro Iwase
Journal:  Oncology       Date:  2019-09-11       Impact factor: 2.935

Review 8.  Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials.

Authors:  Federico Coccolini; Matteo Nardi; Giulia Montori; Marco Ceresoli; Andrea Celotti; Stefano Cascinu; Paola Fugazzola; Matteo Tomasoni; Olivier Glehen; Fausto Catena; Yutaka Yonemura; Luca Ansaloni
Journal:  Int J Surg       Date:  2018-02-20       Impact factor: 6.071

9.  Optimal Cutoff Values of Skeletal Muscle Index to Define Sarcopenia for Prediction of Survival in Patients with Advanced Gastric Cancer.

Authors:  Tatsuto Nishigori; Shigeru Tsunoda; Kazutaka Obama; Shigeo Hisamori; Kyoichi Hashimoto; Yoshiro Itatani; Kazuyuki Okada; Yoshiharu Sakai
Journal:  Ann Surg Oncol       Date:  2018-08-30       Impact factor: 5.344

View more
  3 in total

1.  Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol.

Authors:  Florian Huemer; Stefan Hecht; Bernhard Scharinger; Verena Schlintl; Gabriel Rinnerthaler; Konstantin Schlick; Ronald Heregger; Thomas Melchardt; Angela Wimmer; Iris Mühlbacher; Oliver Owen Koch; Daniel Neureiter; Eckhard Klieser; Sara Seyedinia; Mohsen Beheshti; Richard Greil; Lukas Weiss
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-21       Impact factor: 4.322

2.  Body composition and immunonutritional status in patients treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) for gastrointestinal peritoneal metastases: a prospective single-center analysis.

Authors:  Stefano Rotolo; Andrea Di Giorgio; Marco Cintoni; Emanuele Rinninella; Marta Palombaro; Gabriele Pulcini; Carlo Alberto Schena; Vito Chiantera; Giuseppe Vizzielli; Antonio Gasbarrini; Fabio Pacelli; Maria Cristina Mele
Journal:  Pleura Peritoneum       Date:  2022-03-01

3.  Impact of Low Skeletal Muscle Mass on Complications and Survival for Gastric Cancer: A Propensity Score Matching Analysis.

Authors:  Zhen Fang; Liang Shang; Leping Li
Journal:  Front Surg       Date:  2022-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.